The British company said on Tuesday that revenue rose 8 percent last year to $58,7 billion, thanks to a 14 percent growth in sales of oncology therapies, as well as a 12 percent increase in its respiratory and immunology drugs segment.
Basic earnings per share, a key indicator of profitability in the industry, were $9,16, up 11 percent from 2024. They added that they are on track to reach their goal of $80 billion in annual revenue by 2030. The oral weight loss drug is expected to enter phase 3 clinical trials this year.
Chief Executive Pascal Soriot said AstraZeneca was recording "strong commercial results across all therapeutic areas, with a highly successful portfolio."
"Last year, we announced the results of 16 successful Phase 3 studies and now have 16 medicines with annual sales exceeding $1 billion. The positive momentum in the company continues into 2026 and we expect the results of more than 20 Phase 3 clinical trials during the year. We currently have more than 100 Phase 3 studies, including a significant and growing number of trials of our transformative technologies, which have the potential to revolutionize patient outcomes and drive our growth beyond 2030," said the CEO of AstraZeneca.
AstraZeneca shares have risen by 2,5 percent since the beginning of the year, while in the last 12 months they have recorded a growth of as much as 31 percent.
"Finally, our company's common stock began trading on the New York Stock Exchange on February 2, establishing a harmonized listing structure on the London, New York and Stockholm stock exchanges, allowing a wider range of shareholders to participate in our company's exciting future," said CEO Pascal Soriot.
These results represent an additional boost to the company that is the most valuable on the British capital market.
(AstraZeneca)
